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Abstract
With the growing prevalence of cancer worldwide, research has increasingly focused on
methods of early detection since the early detection of cancer can dramatically improve
health outcomes for affected individuals. Ideally, early detection systems would be highly
reliable yet cost-effective and easy to use. Toward development of such a system, Hirotsu
et al. (2015), developed a “Nematode Scent Detection Test” (NSDT) that capitalizes upon
the attraction of Caenorhabditis elegans nematodes to various tissue samples from cancer
patients to detect multiple types and stages of cancer. However, it is currently unknown
which G-protein coupled receptors (GPCRs), and/or ligands interacting with theses
receptors, cause this attractive behavior in C. elegans. By determining the GPCRs and
ligands responsible, we can develop a detection system that no longer requires the use of
an animal. To lay the groundwork necessary to achieve these goals, my thesis sought to: 1)
validate and expand upon the NSDT for samples derived from a wider variety of patient
types (e.g., tobacco users) and cancer and benign disease types than those tested by Hirotsu
et al. (2015); 2) determine whether nematodes’ chemotactic response to cancer is strain- or
species-specific; 3) and perform a metabolomics literature review to find possible
candidate VOCs that are significantly different in concentration between cancer and
healthy patients.

i

Acknowledgements
Thank you to Dr. Suzanne Estes, my graduate advisor, for taking me on as a graduate
student when I was ready to leave the university. I also want to thank Dr. Estes for her
wonderful edits on my many pieces of writing and guidance on my project. I want to
acknowledge Jennifer Sullins, Ally Yoshioka, Noemi Sarabia Feria, Ariana Montoya and
Brent Bever for all their help on my project from plate making to coming in on weekends
to age-sync. Thank you to Dr. Josiah Wagner and the CEDAR group that provided funding,
expertise and biological samples for this project. I would like to thank my family and
friends for being supportive of me during my graduate program. Finally, thank you to
Portland State University for the Vision 2025 grant to Dr. Suzanne Estes that helped to
fund this project. And finally, I want to thank my committee members for all their advice
on my project.

ii

Table of Contents
Abstract…………………………………………………………………………………….i
Acknowledgements………………………………………………………………………..ii
List of Figures……………………………………………………………………………..v
List of Abbreviations……………………………………………………………………..vii
Introduction………………………………………………………………………………..1
Methods…………………………………………………………………………………..15
Results……………………………………………………………………………………24
Discussion………………………………………………………………………………..36
Conclusions & Future Research………………………………………………………….46
References………………………………………………………………………………..49
Appendix

A.

Table

of

prostate

urine

sample

cohort

patient

information…………………………………………….…………………………………59
Appendix B. Table of metabolomic studies on VOC profiles from both cancer and healthy
patients…………………………………………………………………………………...71
Appendix C. Table of specific VOCs from the metabolomic studies that were significantly
different between cancer and healthy patients………………………………….………..82

iii

Appendix D. Multivariate correlation of entire data set with three sample types (Healthy,
Negative Screen and PAC) ………………………………………………………………83
Appendix E. Multivariate correlation of PAC patient data………………………………84
Appendix F. Multivariate correlation of healthy patient data……………………………85
Appendix G. Multivariate correlation of negative screen patient data…………………..86

iv

List of Figures
Figure 1: Estimated cancer-related deaths in the United States in 2018……………………1
Figure 2: Weaknesses of PSA testing for the early detection system for prostate cancer…..3
Figure 3: Neurological network in C. elegans……………………………………………..8
Figure 4: Chemotaxis behavior of C. elegans with a uniform concentration of attractant...10
Figure 5: GPCR activation via extracellular ligand binding……………………………...11
Figure 6: C. elegans chemotactic response to urine from cancer and healthy patients……12
Figure 7: Hirotsu et al. (2015) C. elegans chemotaxis assay……………………………...16
Figure 8: Chemotaxis assay plate set up………………………………………………….19
Figure 9: A dilution of 10-2 elicits the strongest attractive response of wildtype N2 C.
elegans to HCC and PAC urine…………………………………………………………..24
Figure 10: Wildtype N2 C. elegans are more attracted to urine from HCC patients than to
urine of healthy and liver cirrhosis patients………………………………………………26
Figure 11: Wildtype N2 C. elegans are more attracted to urine from HCC patients than to
urine from healthy and negative screen patients………………………………………….26
Figure 12: Wildtype N2 C. elegans are more attracted to urine from PAC patients than to
healthy and negative screen patient urine………………………………………………...27

v

Figure 13: Wildtype N2 C. elegans are more attracted to urine from PAC patients than to
healthy and negative screen patient urine………………………………………………...28
Figure 14: Wildtype N2 C. elegans are slightly more attracted to urine from PAC patients
categorized as having tumor types 2 and 3 than to those with type 1 or no tumor (type
0)........................................................................................................................................29
Figure 15: N2 Ancestral C. elegans are more attracted to urine from PAC patients than to
healthy and negative screen patient urine………………………………………………...31
Figure 16: C. briggsae are attracted to urine from PAC, healthy and negative screen
patients…………………………………………………………………………………...31
Figure 17: N2 Ancestral C. elegans are attracted to urine from PAC patients…………….32
Figure 18: C. briggsae are attracted to urine independent of type (PAC, healthy and
negative screen)…………………………………………………………………………..32

vi

List of Abbreviations
BMI – Body mass index
CI - Chemotaxis Index
CIs – Chemotaxis Indices
DRE – Digital rectal exam
GPCR – G-protein coupled receptor
HCC – Hepatocellular carcinoma
NaOH – Sodium hydroxide
NGML – Nematode growth medium, lite
NSDT - Nematode Scent Detection Test
PAC – Prostate adenocarcinoma
PSA – Prostate specific antigen
VOC – Volatile organic compound

vii

Introduction
The Worldwide Impact of Cancer and the Need for an Early Detection System
Owing to a lack of early detection diagnostics and ineffective treatments for laterstage cancerous tumors, cancer has become a global phenomenon (Hirotsu et al., 2015).
Cancer is a leading cause of death worldwide, with an estimated 17 million deaths by 2030
(Boyle & Levin, 2008). In the United States alone, there were an estimated 610,000 deaths
and 1.7 million
new

cases

of

cancer that arose
during 2018, with
the majority of
these

cases

resulting

from

breast

and

Figure 1: Estimated cancer-related deaths in the United States in
2018. The top three cancer types for men were lung, prostate and
colon cancer; the top three cancer types for women were lung, breast
and colon cancer. From Siegel et al. (2019).

prostate cancer (Fig. 1) (Siegel, Miller & Jemal, 2019). To combat this epidemic, the
National Institutes of Health (NIH) estimates the United States will spend approximately
$158 billion in 2020 on health care specifically related to cancer, which is an increase of
27 percent from 2010 (https://www.nih.gov/news-events/news-releases/cancer-costsprojected-reach-least-158-billion-2020). Individually, cancer has the highest per-person
medical costs out of the five health conditions that most contribute to high medical costs
in the United States (Narang & Nicholas, 2017). Unfortunately, these individualized costs
1

were expected to grow 40% from 2010 to 2020, a trend attributed primarily to increasing
costs for cancer treatments, health services, and expected changes in demographics.
Additionally, since most individuals who undergo cancer treatment are normally over the
age of 65, Medicare, a federally funded health care program for individuals over 65, will
hold most of the burden (Narang & Nicholas, 2017).
As the burden of cancer increases both domestically and internationally (Siegel, Miller &
Jemal, 2019), research has increasingly focused on methods of early detection since early
detection dramatically improves health outcomes for affected individuals. Unlike other
illnesses, such as diabetes, laboratory diagnostics for cancer remain limited (Schiffman,
Fisher & Gibbs, 2015). Currently, tumor markers—cancer-derived substances that may be
elevated in blood, urine or tissues of individuals with cancer—are the primary system for
early screening of potential cancer cases (Schiffman, Fisher & Gibbs, 2015). For instance,
prostate-specific-antigen (PSA) testing was first utilized in 1979 for diagnosing prostate
cancer (Thompson et al., 2004). A value of 2.6 ng/ml was originally determined to be the
upper end of the normal range for PSA levels in patient serum. Prior to PSA testing,
prostate cancer was diagnosed via a digital rectal exam (DRE), which was ineffective as it
was only able to detect cancer after it had already metastasized. However, if the DRE
results were abnormal, the patient underwent a prostate biopsy with digital guidance to take
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up to four biopsy samples.
A study including data
from multiple institutions
examined PSA values and
DREs from 6,630 men
over the age of 50 and
concluded that the upper
limit for the normal range
of

PSA

should

be

increased to 4 ng/ml of
Figure 2: Weaknesses of PSA testing for the early
detection system for prostate cancer. PSA occurs naturally
in both cancerous and non-cancerous prostate tissue, and there
are many factors that may either decrease or increase PSA
values, independent of cancer within the body, including
exercise, urinary tract infections and various medications.
From cruk.org.

PSA present in patient
serum (Thompson et al.,
2004). However, PSA is
excreted by both malignant

as well as nonmalignant prostate cells and can therefore be present in the serum of patients
(Fig. 2) who have benign diseases such as prostatitis and prostatic hyperplasia (Eastham,
2017). A meta-analysis by Mistry & Cable (2003) found that the sensitivity and specificity
of PSA tests were 72.1% and 93.2%, respectively. Sensitivity is a measurement of how
well a diagnostic test correctly detects a patient with the disease of interest while specificity
shows how well a test correctly distinguishes a healthy patient from a patient with the
disease of interest (Parikh et al., 2007).
3

Additionally, tumor markers for cancer, many of which can also be produced by normal
cells, have shown to be inaccurate and inefficient, especially among the most common
types of cancer (Schiffman, Fisher & Gibbs, 2015). The most common forms of cancer
detection currently in use include the PSA test for prostate cancer, carcinoembryonic
antigen for breast cancer, cancer imaging for multiple cancer types, and biopsies, which
are invasive and often expensive tests that can also lead to overdiagnosis and overtreatment
of different cancer types and stages (Schiffman, Fisher & Gibbs, 2015).
Recently, early cancer detection studies using animal models have become more prevalent.
These studies trained animals with advanced olfactory systems, such as dogs (Cronu et al.,
2011) and mice (Sato et al., 2017), to correctly distinguish cancer from control individuals
using patient urine. Trained dogs were able to detect prostate cancer patient from control
patient urine, independent of cancer stage, with sensitivity and specificity values of 91%
(Cronu et al., 2011). Similarly, mice were trained to distinguish bladder cancer patient urine
from controls and were able to discriminate all eleven bladder cancer patient urine samples
from control patient urine (Sato et al., 2017). However, the cost and time involved in
breeding, housing and training animals to detect cancer are prohibitive. Additionally, the
olfactory systems of such mammals are extremely complex, giving little hope of
determining which receptors or ligands are involved in these animals’ ability to detect
cancer.

4

Cell Cycle Dysregulation and the Progression of Cancer
The normal progression of the cell cycle involves the faithful duplication and eventual
segregation of genetic material into daughter cells. This process ultimately allows for
proper gene expression and production of proteins that regulate metabolic pathways. When
genetic mutations arise, however, cell cycle dysregulation can result. Such mutations can
result from intrinsic sources such as DNA replication errors, or from extrinsic sources such
as exposure to UV radiation from sunlight, carcinogens, or ionizing radiation. The cell
cycle contains many checkpoints to preserve the integrity of the replication process and
ensure that mutations are not transmitted. However, when a mutation negatively affects
checkpoint systems in the cell cycle, outcomes can range from cell death to reprogramming
of the cell cycle, which can lead to cancer formation (Barnum and O’ Connell, 2014).
Due to the high turnover rate of many somatic cell types, the majority of cancers are
sporadic rather than heritable, caused by mutations resulting from replication errors within
these cells (Bertram, 2000). Since adult humans contain around 10 15 cells, a large target
for such mutations exists. Cancers therefore tend to affect cell types with greater
proliferative potential and opportunity for exposure to carcinogens; e.g., epithelial tissue
(Bertram, 2000).
Cancer progresses by reprogramming the metabolic pathways of affected cells to allow
excessive expansion and invasion of various tissue types by cancerous cells (Sarkar et al.,
2013). This uncontrolled cell growth occurs as a result of oncogene activation alongside
deactivation of genes that suppress tumor growth, as well as the down-regulation of
5

apoptotic systems. Cancer hijacks metabolic and protein synthesis pathways to overexpress
various cellular components. For instance, these cells can exhibit a shift to aerobic
glycolysis, consuming massive amounts of glucose for conversion to lactate, which is
secreted from the cell as a byproduct (Vazquez et al., 2016). This process is known as the
Warburg effect (Warburg et al., 1927). As such, these proliferating cells begin to
overproduce glucose transporters and glycolytic enzymes (Heiden & DeBerandinis, 2017).
However, the Warburg effect, also known as aerobic glycolysis, also appears in noncancerous cells that are involved with the immune system, angiogenesis and pluripotency
(Abdel-Haleem et al., 2017). Non-cancerous cells invoke rapid proliferation in response
to many processes such as inflammation, autoimmune disorders and for regulation of
physiological process such as T-cell production (Abdel-Haleem et al., 2017). As a result,
the Warburg effect is associated with rapid proliferation of both cancerous and noncancerous cells (Abdel-Haleem et al., 2017).
Fuel sources beyond glucose are also required for energy conversion, biomass generation,
and control of redox reactions within cancerous cells (Heiden & DeBerandinis, 2017).
Fatty acids, branched chain amino acids, serine, glycine and many other nutrients have
been found necessary for cancer metabolism (Heiden & DeBerandinis, 2017). As
byproducts of this metabolism, cancer cells also secrete a variety of compounds including
volatile organic compounds (VOCs), such as various amino acids, ammonia and urea,
which help to form the tumor microenvironment (Dang, 2017). Such discoveries began a
new area of study known as volotomics, the study profiles of VOCs excreted in the
6

presence and absence of a disease (Borza et al., 2015). VOCs can be measured from various
bodily fluids including, but not limited to: urine, serum, breath, skin, feces and/or saliva.
These VOCs are categorized into exogenous and endogenous. Exogenous VOCs originate
from external factors such as smoking, drugs, ingested foods, and absorption through the
skin, whereas endogenous VOCs arise from both normal and abnormal metabolic processes
(Borza et al, 2015). Many VOC profiles have been determined from different studies
across many cancer types, but currently, no single VOC(s) has proven to reliably
distinguish cancer from healthy sample types.
There is a clear need for an accurate and efficient system for earlier cancer prognoses
(Schiffman, Fisher & Gibbs, 2015). Strides have been made toward increasing and
improving technology available to detect cancer progression in the early stages, saving
lives, money and time; however, diagnostics continue to be specific to advanced stages and
cancer types (Schiffman, Fisher & Gibbs, 2015). Ideally, future early detection systems
would need to be highly reliable across many stages and types of cancer while remaining
cost-effective and easy to use, unlike the currently available technology.
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C. elegans Olfactory System
Caenorhabditis
commonly

elegans

utilized

experimental

as

model

is
an
in

neurobiology because of its
simple nervous system, which
is

primarily

devoted

chemosensation—as

is

to
a

sizeable fraction of its genome
(Bargmann,

2006).

This

species has the exceptional
ability to detect a wide variety

Figure 3: Neurological network in C. elegans. Within
the amphid sheath cells of the neurological network in the
head of C. elegans, there are a series of neurons that are
involved in chemotaxis behaviors, both attractive (AWA
and AWC) and repellant (ASH, ADL and AWB). From
[A] Hall et al. (1991) & [B] Perkins (1986).

of volatile and water-soluble compounds necessary to differentiate food, mates, pathogens
and predators encountered in its natural environment (Bargmann et al., 1993; Bargmann,
2006). C. elegans is a bactivorous species whose natural habitat is decaying vegetation,
which involves low oxygen and high humidity (Schulenburg & Félix, 2017). Thus, C.
elegans can be reliably found in vegetable gardens, orchards, wooded areas and compost
heaps across all continents except Antarctica (Schulenburg & Félix, 2017). However, since
limited natural sampling of C. elegans has been conducted, there may be additional habitats
in which C. elegans thrive (Schulenburg & Félix, 2017; Kiontke and Sudhaus 2006).
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C. elegans hermaphrodites have 302 neurons, which fall into 14 different categories, five
of which detect volatile chemicals. One group, known as amphid neurons, are located in
the head of the worm and include the AWA, AWC, ASH, ADL and AWB neurons
(Bargmann et al., 1993; Fukuto et al., 2004). ASH, ADL and AWB neurons are used to
detect repellent chemicals whereas AWA and AWC neurons detect attractive substances
(Fig. 3) (Fukuto et al., 2004). Currently, there are two known ligands for C. elegans Gprotein coupled receptors (GPCRs): diacetyl and 2-heptanone (Sengupta, Chou &
Bargmann, 1996; Zhang et al., 2016). Diacetyl binds to odr-10, a GPCR embedded in the
attractive AWA amphid neuron, causing an attractive behavioral response (Sengupta, Chou
& Bargmann, 1996). 2-heptanone binds str-2, a GPCR found embedded in the attractive
AWC amphid neuron, eliciting an attractive response from C. elegans (Zhang et al., 2016).
In response to chemical stimuli, C. elegans movement involves two behaviors: sinusoidalswimming movements called “runs” and sharp turns called “pirouettes” (PierceShinmomura, Morse & Lockery, 1999). Pirouettes occur when the C. elegans head curls
back towards its tail, known as an “omega turn”. When a C. elegans is placed on an agar
plate with a uniform dispersal of 2 mM NH4Cl, a known attractant, they respond making
many runs and pirouettes, advancing toward the chemical stimulus (Fig. 4a). By tracking
and analyzing the movements of multiple such C. elegans, Pierce-Shinmomura, Morse &
Lockery (1999) developed a map showing the probability of C. elegans movement to
various locations on an agar plate containing a uniform concentration of attractant (Fig.
4b). From this, they determined that C. elegans primarily remained in a 1 cm diameter from
9

their initial starting point (Fig.
4b), also documenting the mean
and variance of animal speed,
turning rate and turning bias
(Fig. c-e). From such data, the
authors showed that, in the

Figure 4: Chemotaxis behavior of C. elegans with a
uniform concentration of attractant. [A] Three C.
elegans movement tracks on an agar plate with a
uniform concentration of 2 mM NH4Cl, run
independently. [B] The probability per unit of area
movement of individual C. elegans’ based on 47
individual runs. [C-E] Speed, turning rate, and turning
bias for the individual C. elegans tested in B. From
Pierce-Shinmomura, Morse & Lockery (1999).

presence

of

attractant,

C.

a

uniform

elegans

will

remain at their initial locus
unless a stronger attractant is
present,
their

thus

demonstrating

chemical-dependent

olfactory system.
The detection of attractive compounds is thought to be mediated by binding and subsequent
phosphorylation of G protein-coupled receptors (GPCRs) expressed in the AWA and AWC
emosensory neurons (Fig. 5). GPCRs are responsible for processing olfactory signals
(Fukuto et al., 2004) and transducing signals for a variety of other biological processes.
For olfaction to occur, a ligand must interact with a G-protein coupled receptor (GPCRs)
on the membrane of neurological cells (Fig. 5) (Sengupta et al., 1996). Only two of the
estimated 1,000 – 2,000 GPCRs in C. elegans have known ligands as named above
(Bargmann et al., 1993; Tobin, 2008; Vidal et al., 2018).
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C. elegans Use in Early Cancer Detection
Hirotsu et al. (2015) developed a “Nematode Scent Detection Test” (NSDT) that capitalizes
on the ability of C. elegans to sense cancer via olfaction. Cancer cells excrete numerous
compounds as metabolic byproducts—
many of the same byproducts generated
by lactic acid bacteria, a primary C.
elegans’ food source to which it is
strongly attracted (Lee et al., 2017). For
instance, bacteria emit a variety of
Figure 5: GPCR activation via extracellular
ligand binding. When the ligand for the GPCR
binds, the GPCR changes conformation and
allows for the activation of a G protein-coupled
receptors (GPCRs) downstream in the pathway
when GDP is exchanged for GTP on the alpha
subunit. Once the alpha subunit is active, the
beta and gamma subunits detach from the alpha
subunit to allow their signal transduction. From
Belmonte & Burns (2011).

volatile organic compounds (VOCs), and
several of these VOCs (e.g., acetone and
benzaldehyde) are also found in exhaled
breath from patients with several cancer
types including lung and pancreatic

cancer (Barash et al., 2009; Hirotsu et al., 2015; Markar et al., 2018).
Hirotsu et al. (2015) found that, when C. elegans were given the choice between healthy
and cancerous urine samples, they had an overwhelming preference for the samples from
cancer patients regardless of the stage (including stage 0) or type of cancer presented (Fig.
6) (Hirotsu et al., 2015). Specifically, C. elegans tended to chemotax toward cancer urine
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samples at a dilution of 101

and away from healthy

urine samples presented
on a Petri plate, which
were

quantified

positive

and

“chemotaxis
(CIs),

as

negative
indices”

respectively.

Specifically, they showed
that urine samples from patients
with different types and stages of
cancer

at

a

10-1 dilution,

Figure 6: C. elegans chemotactic response to urine
from cancer and healthy patients. Chemotaxis of wild
type C. elegans to diluted urine samples from cancer
patients (yellow) compared to healthy individuals (blue)
at a 10-1 dilution. Error bars represented SEM. From
Hirotsu et al. (2015).

generally elicited positive CIs
while control samples elicited either no response or were slightly repulsive to worms,
represented by a negative CI (Fig. 6). More specifically, the chemotaxis index (CI)
measured for a population of age-synchronous worms describes the proportion of worms
that migrated to a stimulus as [(number migrating to sample of interest) – (number not
migrating to sample of interest)] / (all worms). A positive CI indicates an overall preference
for the sample of interest. Hirostu et al. measured a positive average CI of around 0.3 for
urine samples taken from cancer patients diagnosed with different types and stages of
cancer, suggesting that there are specific compounds shared among the cancer types tested
that are attractive to C. elegans. Nematodes were similarly attracted to diluted urine from
12

cancer patients and repulsed by urine from healthy individuals (Fig. 6). Conversely, C.
elegans could not reliably distinguish serum samples from cancer affected versus healthy
individuals, perhaps due to other interfering substances present in serum.
Hirotsu et al. (2015) utilized urine samples stored at -20°C prior to testing from only pretreatment patients and excluded patients on the basis of age (> 20 years old), physical
symptoms (e.g., headache, chest or abdominal distension, appetite, weariness, cough,
bloody feces, constipation, and diarrhea), pregnancy, current medicine usage, alcohol
usage (<3 days per week a drink was consumed), and tobacco use (less than 2 weeks prior
to participating). Whether the NSDT is useful for additional cancer types and in wider
variety of patient and sample types remains untested.
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Research Aims
Because the ligand-receptor interactions that fuel C. elegans chemotactic behavior are not
currently known, we have essentially no known candidate GPCRs or ligands that may be
responsible for C. elegans cancer detection. Identifying these interactions (or the cancer
metabolite that C. elegans is detecting when it “smells” cancer) would allow for
development of an animal-free early detection system. To lay the groundwork necessary to
achieve these goals, my thesis expands upon the work of Hirotsu et al. (2015) to: 1) validate
and expand upon the NSDT for samples derived from a wider variety of patient types (e.g.,
tobacco smokers) and cancer and benign disease types; 2) determine whether nematodes’
chemotactic response to cancer is strain- or species-specific; 3) and perform a
metabolomics literature review to find possible candidate VOCs that are significantly
different in concentration between cancer and healthy patients.
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Methods
Nematode strains and culture conditions. Three separate strains of nematodes were
utilized in chemotaxis assays: the standardly utilized wildtype Bristol N2 (referred to
hereafter as “N2”), an “ancestral N2” strain, and a strain of C. elegans’ congener species,
C. briggsae, PB800. The ancestral N2 strain was isolated and cryogenically stored in 1968,
while the standardly utilized N2 experienced many generations of lab culture before being
cryogenically stored as separate strain in 1980 (WormBase).
Following Hirotsu et al. (2015), nematodes were maintained at 20 °C on NGM Lite
(NGML) plates seeded with NA22 E. coli as a food source. Prior to all experiments, strains
were allowed to recover from freezing for two to three generations prior to being age
synchronized by standard bleach treatment.
Age-synchronization. In accordance with Hirotsu et al. (2015), young adult stage
nematodes were used for all chemotaxis assays. Mixed populations of nematodes were
grown on NGM Lite (NGML) plates seeded with NA22 E. coli. Nematodes were washed
into 15 ml conical tubes with S-Basal buffer (100mM NaCl, 5.75mM K 2HPO4, 45mM
KH2PO4, and Milli-Pore water). The conical tubes were spun at 800 rpm for 1 minute, and
the supernatant was poured off. Nematodes were washed 3 more times with 15 ml of SBasal buffer at 800 rpm for 1 minute prior to bleaching for age synchronization. To release
eggs from the adult nematodes, samples were treated with a 1:2 solution of 5M sodium
hydroxide (NaOH) and 2.75% bleach, respectively. After the third wash, 5 ml of S-Basal
buffer was added to each conical tube, followed by 2 ml of the NaOH-bleach solution.
15

Every 2 minutes, the conical tubes were inverted 4-6 times. After approximately 12
minutes, the adults break apart, releasing eggs. The conical tubes were then quickly spun
down at 800 rpm for 1 minute, and the supernatant poured off. Samples were again washed
3 times with 15 ml of S-Basal buffer at 800 rpm for 1 minute. After the final wash, the
supernatant was poured off, and the remaining 1 ml of buffer and egg solution, was pipetted
onto NGML plates seeded with NA22 E. coli. The plated eggs were kept at 20 ºC for 72
hours at which time they had reached the young adult stage.
Specific Aim 1. Validate and expand on Hirotsu et al. NSDT for samples derived from
a variety of patient, cancer and benign disease types.
Hirotsu et al. (2015) NSDT. I
first utilized the chemotaxis
assay of Hirotsu et al. (2015),
which used unseeded 9 cm Petri
plates containing NGML and
200 mg/ mL streptomycin that
were marked to contain three
sections (Fig. 7). Points A and B
are 2.5 centimeters from the
center of the plate. Prior to
plating the diluted urine samples,
1 µl of 1 M sodium azide (NaAz)

Figure 7: Hirotsu et al. (2015) C. elegans chemotaxis
assay. 50-100 wildtype N2 C. elegans are plated onto
the midline of a 9 cm plate treated with an attractant
(side A) and control (side B), each 2.5 cm from the
center. 1 µl of NaAz was plated on points A and B prior
to plating the attractant and control to kill C. elegans
once they reached either point A or B. A center area
0.5 cm wide is marked to control for C. elegans that are
unable to move or chemotax and will therefore not be
included in the CI calculations. C. elegans are allowed
to chemotax for 30 minutes. A CI was determined from
counts of animals that did and did not move toward the
attractant.

16

was plated on points A and B to kill C. elegans’ chemotaxing towards either point A or B.
On point A, 1 µl of sample was plated while on point B, 1 µl of control was plated. To
control for C. elegans that were incapable of movement or scent detection, a third section
was created 0.5 cm from the center of the plate. After 30 minutes, C. elegans that
chemotaxed into sections A and B were counted and a CI was determined for each sample
as CI = [(number migrating to sample of interest) – (number not migrating to sample of
interest)] / (all worms).
Urine and serum samples. Urine samples from patients were obtained from collaborators
at The Knight Cancer Institute's Cancer Early Detection Advanced Research Center
(CEDAR, Portland, OR). We obtained two cohorts of urine samples: “HCC” and “PAC”.
The HCC cohort contained 3 patients for each of three sample types: hepatocellular
carcinoma (HCC), healthy, and liver cirrhosis. The PAC cohort contained 20 urine samples
from prostate adenocarcinoma (PAC) patients, 19 samples from healthy patients, and 28
samples from “negative screen” patients (Appendix A). For the HCC cohort, healthy
patients were deemed as those who did not have HCC or liver cirrhosis. For the PAC
cohort, healthy patients had high PSA levels but upon a biopsy of their prostate tissue, their
tissue was either normal or benign; and negative screen patients, had low PSA values
(Appendix A). For the HCC cohort, urine samples were frozen immediately upon
collection, thawed and aliquoted, then stored at -80°C as 50 µl aliquots prior to being
thawed for each chemotaxis assay setup. For the PAC cohort, urine samples were frozen
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immediately upon collection, thawed at room temperature, and freshly diluted using
autoclaved milliQ water prior to each chemotaxis assay setup.
For the PAC cohort, we received clinical data for each patient including at least
some of the following: PSA (ng/ml), clinical diagnosis, prostate volume (cm 3), tobacco use
(yes = 1/no = 0), body mass index (BMI) (kg/m 2), age at time of sample collection, and
tumor grade (Gleason score for each tumor) (Appendix A). If a patient develops a
cancerous tumor, the “Gleason grading system” is used to score its severity by evaluating
the different histological patterns that arise in various stages of prostate cancer (Gordetsky
& Epstein, 2016). The Gleason grading system was derived from a study conducted
through the Veteran’s Affairs Cooperative Research Group between 1959 and 1964 by
pathologist, Donald Gleason. Gleason noted that prostate tissue was composed of primarily
two histological patterns and therefore added the two grade patterns together, each on a
scale of 1-5, to create an overall Gleason score on a scale of 2-10 (Gleason & Mellinger,
1974; Gordetsky & Epstein, 2016). With both histological grade groups (1-5) and Gleason
score values (2-10) the higher the value the more severe the prostate cancer prognosis. Two
patients can have the same Gleason score value but have different severities. For example,
a Gleason score of 7 can result from two grade group combinations of either 3+4 or 4+3,
with 4+3 being more severe than 3+4. This means that a patient with 4+3, and a Gleason
score of 7, would have a histological grade group of 4 most prevalent and 3 the second
most prevalent. Additionally, higher stages of prostate cancer (i.e., stages 3 and 4) usually
result in a Gleason score of 7 and above, while lower stages of prostate cancer (i.e., 1 and
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2) usually result in a Gleason score of less than 7 (Gleason & Mellinger, 1974; Gordetsky
& Epstein, 2016).
Alterations to NSDT. After an extensive series of pilot tests demonstrating that C. elegans
exhibited weak and variable
chemotactic responses to HCC
and PAC samples alongside a
weak attraction to 1 M NaAz,
which

was

used

to

kill

nematodes in the Hirotsu assay,
I devised a modified NSDT.
Following Margie et al. (2013),
unseeded

NGML

plates

prepared without streptomycin
were divided into 4 equally
sized quadrants (Fig. 8). A
circle with a diameter of 1 cm

Figure 8: Chemotaxis assays plate set up. 1µl of a
diluted urine sample was plated on the T1 and T2 spots,
which were 2.5 cm from the origin. 1 µl of autoclaved
milliQ water was placed on both the C1 and C2 spots. The
origin circle had a diameter of 1cm, where ~50 young
adult C. elegans were plated.

was drawn around the center of
the plate. Quadrants across from one another, were labelled with “T” for the sample and
the other two quadrants were labelled “C” for control. Each quadrant contained a dot
exactly 2.5 cm from the center of the plate for placement of 1 µl of each sample or control.
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After each chemotaxis plate was prepared, approximately 50 washed, young adult C.
elegans were plated in the center (Fig. 8). We further controlled for light and surrounding
odors by using clean, unscented towels to cover the chemotaxis plates during assays. The
plates were left on the benchtop, covered with towels for 1 hour at 21 °C. After 1 hour,
the plates were individually imaged and the number of C. elegans in each quadrant was
recorded.
To determine the CI, the previously described equation was used where T 1 + T2
was the number of C. elegans that chemotaxed into the quadrants with the diluted urine
samples, and C1 + C2 is the number of C. elegans that chemotaxed into the quadrants with
the controls (Fig. 8). The CI in this case is the total number of C. elegans that chemotaxed
towards a diluted urine sample, minus the total number of C. elegans that chemotaxed
towards the control, divided by the total number of C. elegans in each quadrant. To control
for C. elegans that were immobile or incapable of olfaction, all animals in the 1 cm circle
near the center were left uncounted (Fig. 8).
Data analysis. Using a nested analysis of variance (ANOVA), differences in nematode
chemotactic responses to different urine types (healthy, benign disease and cancer), and to
different patients within each sample type, were determined for the liver (HCC) and
prostate (PAC) cancer cohorts separately. The model y =  + type + individual(type) + 
was tested in each caseVAs were followed by post hoc Tukey’s honestly significant
difference (HSD) tests ( = 0.05) using least squares means to test for differences between
individual pairs of sample types.
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Since a variety of clinical data were available for the PAC cohort, pairwise correlation
coefficients were calculated between various clinical traits and between these traits and the
average CIs for each patient. For these analyses, we also created a trait, “tumor type”,
coded as 0 for normal tissue, 1 for benign tissue, 2 for cancerous tumor with a Gleason
score of 3+3 or 3+4, and 3 for any cancerous tumor with a Gleason score of 4+3 or above.
Correlations were calculated using the entire dataset and, where appropriate, each urine
type (PAC, healthy, negative screen).
Sensitivity and specificity calculations. Following Hirotsu et al. (2015), sensitivity and
specificity were calculated for each sample set and each nematode strain. Sensitivity was
calculated as the total number of true positives over the combined number of true positives
and false negatives, while specificity was calculated as the total number of true negatives
over the combined number of true negatives and false positives. True positives were
positive CI values that correctly detected cancer, while true negatives were negative CI
values that correctly detected samples from either healthy or benign disease patients. False
positives were negative CI values that incorrectly detected samples from either healthy or
benign disease patients, while false negatives were positive CI values that incorrectly
detected cancer.

Specific Aim 2. Determine whether nematodes’ chemotactic response to cancer is
strain- or species-specific. Chemotaxis assays were performed as described above using
N2 ancestral C. elegans and C. briggsae using urine from a subset of PAC cohort patients.
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The same nested ANOVA model was tested for each strain to test the effect of sample type
(PAC, healthy, negative screen) on CIs. These analyses were again followed by Tukey’s
HSD tests.

Specific Aim 3. Identify candidate VOC ligands.
Toward the goal of identifying candidate ligands to utilize in future NSDT assays, I
conducted a preliminary literature review of 19 cancer metabolomic studies. Metabolomic
studies performed on multiple types of cancer were analyzed for VOCs that were
statistically significantly over- or underrepresented in cancer patients compared to healthy
patients. These studies were included based on the age of the paper, number of control
samples compared to the number of cancer samples tested, whether the samples came from
individuals treated for cancer or not, how many VOCs were found in their study, and how
many factors were controlled for (Appendix A). More specifically, I chose papers that were
published no earlier than 2012 seeing that the capabilities of research for detecting specific
VOCs has matured extensively since that time. I also found that papers published prior to
2012 often stated that VOC profiles were different overall between cancer and healthy
patients without identifying any specific VOCs. For the number of samples tested, I
eliminated papers that had fewer than 15 total patient urine, serum or breath samples;
however, for papers that used cell culture, I eliminated papers that had fewer than three
different cell lines. I also eliminated papers that controlled for fewer than three external
variables. These variables included smoking status, body mass index, exercise habits, diet
22

and many others. Additionally, I eliminated publications that reported fewer than two
VOCs in their findings to prevent papers with biases for specific VOCs. The VOCs found
to be statistically significantly different between control samples and cancer samples
among these studies were compiled. I also used the Human Metabolomic Database
(http://www.hmdb.ca/) to compile VOC information including chemical formula, natural
state of the VOC, and whether the VOC is considered to be of endogenous or exogenous
origin.
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Results
Specific Aim 1. Validate and expand Hirotsu et al. NSDT for samples derived from a
variety of patient, cancer and benign disease types
Following the exact methods of Hirotsu et al. (2015), we tested a series of dilutions (0,
1:10, 1:25,1:50) made from healthy, liver cirrhosis and hepatocellular carcinoma (HCC)
sample types using autoclaved MilliQ water. These assays included many technical
replicates from three individuals of each type. We found no significant difference between
average CIs for any dilution of HCC urine compared to the urine from patients with liver
cirrhosis and patients that were healthy (data not shown). Because we were unable to
A

B

Figure 9: A dilution of 10-2 elicits the strongest attractive response of wildtype N2 C.
elegans to HCC and PAC urine. (A) Average CI obtained from HCC patient urine samples
at three dilutions (n = 3 patients, 18-22 assays each). (B) Average CI obtained from PAC urine
samples at five dilutions. Error bars represent 1 S.E.M.

replicate the results of Hirotsu et al. (2015), we adapted the methodology of Margie et al.
(2013) for our chemotaxis assays, which allowed us to additionally control for random
movement, surrounding odors and light that could affect C. elegans behavior.
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Using the methodology of Margie et al. (2013), we tested two cancer types: hepatocellular
carcinoma (HCC), and prostate adenocarcinoma (PAC). For HCC controls, we again used
urine from patients diagnosed with liver cirrhosis and patients that were confirmed healthy.
For PAC comparators, we tested urine from patients who were determined healthy from a
PSA blood test (“Negative Screen”) and urine from patients who had high PSA levels but,
when biopsied, were determined not to have cancer (“Healthy”). We utilized the same
dilution series used by Hirotsu et al. (2015) 10-1, 10-2 and 10-3 and, like this paper, found
that a dilution of 10-2 elicited the greatest and most consistent attractive response of worms
to patient HCC and PAC samples compared to those from benign disease and healthy
samples (Fig. 9). Therefore, a dilution of 10-2 was used in all remaining experiments.
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Hepatocellular Carcinoma (HCC) sample cohort
Individually, assays of HCC
patient urine showed primarily
positive

CIs

on

average

whereas those using liver
cirrhosis and healthy patient
urine exhibited negative CIs
(Figs. 10 & 11). Our modified
NSDT had a sensitivity of
67% and a specificity of 83%
for distinguishing HCC from

Figure 10: Wildtype N2 C. elegans are more attracted
to urine from HCC patients than to urine of healthy
and liver cirrhosis patients. Average CI for individual
patient urine samples: HCC (blue), healthy (red) and liver
cirrhosis (orange) (n = 6-10 assays each). Error bars
represent 1 S.E.M.

both healthy urine and urine from
patients with liver cirrhosis. Using
a nested ANOVA testing the
model

y

=



+

type

+

individual(type) + average CIs
varied significantly among both
sample types (F2 = 6.77; p = 0.002)
Figure 11: Wildtype N2 C. elegans are more
attracted to urine from HCC patients than to
urine from healthy and negative screen patients.
A dot plot of average CIs of each patient urine
sample (n=6-10 assays per patient).

and among individuals within each
type (F6 = 2.73, p = 0.021), and a
post hoc Tukey’s HSD test ( =
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0.05) using least squares means revealed that HCC samples elicited significantly more
positive chemotactic responses than either cirrhosis or healthy types.

Prostate adenocarcinoma (PAC) sample cohort
Since a dilution of 10-2 yielded the best results in preliminary assays (Fig. 9), we used this
dilution for remaining PAC cohort assays. Considering all individuals in the full PAC
cohort (n = 67), patients of different types (PAC, healthy, negative screen) exhibited no
statistically significant differences from each other in terms of tobacco use, BMI, age, or
prostate size (1-way ANOVA testing the model: y =  + type + ); however, healthy

Figure 12: Wildtype N2 C. elegans are more attracted to urine from PAC patients than
to healthy and negative screen patient urine. Average CI for each patient: PAC (blue),
healthy (red) and negative screen (green) (n = 4-24 assays per individual). Error bars represent
1 S.E.M.

individuals tended to have slightly larger prostate sizes on average (55.1 cm 3 compared to
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40.0 cm3 for PAC and 40.7 cm3 for negative screen individuals). As expected, significant
differences among types existed for their defining features: 1) PSA level (F 2 = 20.85, p <
0.0044) such that negative screen individuals had substantially lower PSA levels (1.79
ng/mL on average) compared to PAC and healthy types (7.07 and 7.17 ng/mL on average,
respectively) (Tukey’s HSD,  = 0.05); and 2) tumor type, with PAC having tumor types
of 2 or 3; healthy with type 1; negative screen with types 0 or 1.

Independent of cancer stage,
urine
tended

from
to

PAC
elicit

patients
generally

positive CIs compared to urine
from healthy and negative
screen individuals (Figs. 12 &
13. Using a nested ANOVA
testing the model y =  + type
+ individual(type) +  there
was

significant

variance

among types (F2 = 6.22, p =

Figure 13: Wildtype N2 C. elegans are more attracted to
urine from PAC patients than to healthy and negative
screen patient urine. A dot plot of average CIs for each
patient. (n=19-27 patients; 4-24 replicate assays per
patient).

0.002) and among individuals within type (F64 = 1.48, p = 0.014). A post hoc Tukey’s
HSD test ( = 0.05) using least-squares means showed that average CIs for PAC types
were significantly higher than both that of healthy and negative screen types.
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From the average CIs, a sensitivity of 81% and a specificity of 61% was calculated for
detecting PAC from controls: healthy and negative screen urine samples. In comparison,
using the PSA values from clinical diagnostics associated with each patient yielded a
sensitivity and specificity of the PSA blood test as 88% and 59%, respectively.
Looking

across

“tumor

type”

categories

(0-3),

chemotactic indices
were

somewhat

predictive of types 2
and

3,

but

completely unable to
distinguish

benign

tumors (type 1) from
healthy (type 0) (Fig.
14).

A

1-way

Figure 14: Wildtype N2 C. elegans are slightly more attracted
to urine from PAC patients categorized as having tumor types
2 and 3 than to those with type 1 or no tumor (type 0). Average
CIs (1 S.E.M.) for each patient type (n = 8-23 per type): 0 (-0.025,
0.020), 1 (-0.025, 0.020), 2 (0.046, 0.024), 3 (0.046, 0.035).

ANOVA testing the model y =  + type + found only a marginally significant difference
among tumor categories with respect to average CI (F3 = 2.75, p = 0.049). A post hoc
Tukey’s HSD comparison could not detect statistically significant differences between CIs
of any pair of samples types.
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Associations between CI values and patient clinical profile features
We assessed pairwise associations between average CIs and aspects of patient clinical
profiles; i.e., PSA, tobacco use, body mass index (BMI), prostate size, age at time of urine
collection, and tumor type (0 = none; benign = 1; Gleason score cancerous 3+3 and 3+4 =
2; Gleason score 4+3 and above=3) for the entire set and by each type (PAC, healthy or
negative screen) (Appendices D-G). First considering the entire data set, statistically
significant correlations included those between average CI and prostate size (r = -0.307, p
= 0.027), average CI and tumor type (r = 0.251, p = 0.041), PSA value and prostate size (r
= 0.275, p = 0.040), and PSA value and tumor type (r = 0.602, p < 0.0001) (Appendix D).
Next assessing bivariate relationships within separate patient groups, there were no
statistically significant correlations for PAC patients (Appendix E). However, there was a
statistically significant correlation between PSA value and prostate size (r = 0.5447, p =
0.0227) for healthy individuals (Appendix F), and between PSA value and prostate size (r
= 0.5035, p = 0.0473) for negative screen individuals (Appendix G).
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Specific Aim 2. Strain- and
species-specific

chemotactic

responses
To understand whether the results
described

above

particular

to

the

would

be

laboratory-

adapted wildtype N2 C. elegans
strain, we performed the same
chemotaxis assays—again using
PAC-cohort urine diluted at 10-2—
with an “ancestral” strain of N2 C.

Figure 15: N2 Ancestral C. elegans are more
attracted to urine from PAC patients than to healthy
and negative screen patient urine. An average CI for
each individual patient urine sample: PAC (blue),
healthy (red) and negative screen (green) (n=6-10
assays). Error bars represent 1 S.E.M.

elegans that should be less lab adapted,
and with a congener, C. briggsae.
Similar to the lab-adapted strain,
ancestral C. elegans exhibited a
preference for PAC urine over healthy
and negative screen but were less able
to distinguish between cancer and
Figure 16: C. briggsae are attracted to urine from
PAC, healthy and negative screen patients.
Average CI for each patient urine sample: PAC (blue),
healthy (red) and negative screen (green) (n = 6-10
assays each). Error bars represent 1 S.E.M.

control samples (Figs. 15 & 17).
Using a nested ANOVA testing the
model

y

=



+

type

+
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individual(type)

+



there

was

significant variance among types (F2 =
3.506,

p

=

0.0320)

and

among

individuals within type (F12 = 2.286, p <
0.0001). But a post hoc Tukey’s HSD
comparison could not detect statistically
significant differences between CIs of
any pair of samples types.

Figure 17: N2 Ancestral C. elegans are
attracted to urine from PAC patients. A
dot plot of the average CI of each
individual: PAC (blue), healthy (red) and
negative screen (green) (n = 4 patients; 610 assays each).

C. briggsae had a different response to the
urine from PAC, healthy and negative
screen patients compared to that observed
for C. elegans. Generally, C. briggsae
were determined to have an overall
Figure 18: C. briggsae are attracted to urine
independent of type (PAC, healthy and
negative screen). A dot plot of the average CI of
each individual: PAC (blue), healthy (red) and
negative screen (green) (n = 4 patients; 6-10
assays each).

attractive response to urine independent
of type (PAC, healthy and negative
screen) (Figs. 16 & 18). Using the same
nested ANOVA model y =  + type +

individual(type) +  there was no significant variation in CIs among types (F2 = 1.578, p
= 0.212) or among individuals within type (F9 = 0.917, p = 0.514).
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Specific Aim 3. Identifying candidate VOC ligands
I conducted a literature review of 19 metabolomic studies of various types of cancer. From
these studies, several compounds were detected at elevated concentrations in the
metabolomic profiles of cancer patients compared to those of healthy individuals
(Appendix B). These studies encompassed many types and stages of cancer, as well as
tissue types, with the metabolomic profiles being derived from fluids including serum,
exhaled breath, cell culture and urine (Appendix B). Several the studies identified
benzaldehyde and decane based compounds as having significantly different
concentrations between cancer and healthy patients (Appendix B).
Decane was found by seven studies to be significantly differentially expressed within the
VOC profiles of individuals with multiple types of cancer (oral, lung, prostate, breast,
and renal) compared to healthy patients (Appendices B & C). However, decane appeared
in multiple forms across these studies, including the isomers: 3,7-dimethylundecane,
dodecane, hexadecane, nonadecane, tetradecane and undecane (Appendix C). All of these
compounds were found to be overrepresented in all cancer and sample types tested
(Bouza et al., 2017; Thriumani et al., 2018; Handa et al., 2014; Wang et al., 2012; Hadi et
al., 2017; Wang et al., 2016).
Among the above compounds, 3,7-dimethylundecane was found to be overrepresented in
the exhaled breath of patients with oral squamous cell carcinoma along with dodecane,
hexadecane, and undecane (Bouza et al., 2017). Dodecane was found at elevated
concentrations in the breath and bronchoscopic tissue of adenocarcinoma lung cancer
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patients with a specific epidermal growth factor receptor (EGFR) mutation (Handa et al.,
2014), and in the exhaled breath of breast cancer patients (Phillips et al., 2010). Wang et
al. (2012) found nonadecane to be present in exhaled breath, lung cell culture and lung
tissue from patients with either lung adenocarcinoma, small cell lung, or lung squamous
carcinoma cancer. Finally, tetradecane concentration was found to be significantly
elevated in the serum of pre-operative breast cancer patients (Hadi et al., 2017) as well as
in urine from patients with renal cell carcinoma (Wang et al., 2016).
Additionally, various aldehydes, a group previously identified as a potential biomarker
for cancer (Rodrigues et al., 2018; Fuchs et al., 2010; Poli et al., 2010) were identified
across multiple studies including benzaldehyde, decanal, hexadecanal, nonanal, and
pentanal (Appendix C). Within the first group, 4-methylbenzaldehyde was present at
significantly reduced concentrations in prostate cancer cell lines compared to healthy
prostate epithelial cell lines (Lima et al., 2018), while five other studies found
benzaldehyde concentrations to be significantly elevated in cancer samples (bladder,
lung, oral) compared to healthy samples regardless of sample type (urine, serum, cell
culture, breath) (Rodrigues et al., 2018; Jia et al., 2018; Roś-Mazurczyk et al., 2017;
Bouza et al., 2017). Jia et al. (2018) found that benzaldehyde concentrations were
elevated in lung large cell carcinoma compared to both lung adenocarcinoma and lung
squamous carcinoma cell culture lines; however, benzaldehyde was generally elevated in
lung cancer patients, regardless of type, compared to healthy patients. Similarly, RośMazurczyk et al. (2017) determined that benzaldehyde was significantly overexpressed in
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serum from patients with both lung adenocarcinoma and squamous cell carcinoma. In a
study of exhaled breath from patients with oral squamous cell carcinoma, Bouza et al.
(2017) determined that benzaldehyde concentrations were significantly increased
compared to the exhaled breath from healthy patients. Rodrigues et al. (2018) found that
benzaldehyde was also significantly overexpressed among three bladder cancer cell lines
compared to healthy bladder cells.
Finally, several ketones were identified as potential differentiators of cancer from healthy
VOC profiles, including: 2-octanone; 3-octanone; 2,6-di-t-butyl-4-hydroxymethylene2,3,5,6-detetrahydrocyclohexanone; cyclohexanone; 2-butanone; 3-heptanone; 4heptanone; and 2-nonanone (Appendix C). Of these compounds 2,6-di-t-butyl-4hydroxymethylene-2,3,5,6-detetrahydrocyclohexanone; 2-butanone; 3-heptanone; and 2nonanone were elevated in prostate (urine), lung (exhaled breath), renal (urine), and
bladder cancer (cell culture), while 3-octanone was elevated in lung cancer (urine) but
reduced in prostate cancer (urine) compared to healthy (Appendices B & C). Last, 2octanone, and cyclohexanone were both reduced in prostate cancer (urine) while 4heptanone was reduced in renal cancer (urine) (Appendices B & C).
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Discussion
There is a demand for a cost-efficient and non-invasive cancer detection system that is
effective across cancer types and stages. Although there are a few early detection tests
such as PSA for prostate cancer, non-invasive tests for other cancer types do not exist.
Rather, diagnostic methods for most cancer types are both invasive and rarely begun until
a patient has reached later stages of disease progression (Hirotsu et al., 2015; Thompson
et al., 2004). It has been well established through metabolomics studies that VOC profiles
of patients with cancer are different from those of healthy patients (Bouza et al., 2017;
Hadi et al., 2017; Wang et al., 2012). However, these studies have so far failed to identify
particular VOCs that consistently and reliably diagnose cancer. Taking advantage of the
advanced olfactory capabilities of certain organisms may provide the foundation for noninvasive early detection tests (Sato et al., 2017; Cronu et al., 2011).
Recent research has attempted to exploit the olfactory systems of both mice (Sato et al.,
2017) and dogs (Cronu et al., 2011) for cancer detection; however, both animals require
behavioral training to be effectively utilized for this purpose. Conversely, C. elegans
relies almost exclusively on its primal olfactory system to engage with and navigate its
environment. This system is highly attuned for detecting VOCs, as its primary functions
include detection of bacterial food sources and pheromones produced by potential mates
(Bargmann et al., 1993; Bargmann, 2006). As such, C. elegans have shown promise for
detecting cancer patients from healthy individuals with no requirement for behavioral
training (Hirotsu et al., 2015).
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Failure to validate Hirotsu et al. (2015) NSDT
Despite considerable effort, I failed to replicate the results of Hirotsu et al. (2015). There
are several potential reasons for this. First, Hirotsu et al. (2015) controlled for a variety of
variables among their patient cohort, while our cohort was more diverse. For example,
they excluded participants based upon various physical symptoms (i.e., headache, bloody
feces, alcohol consumption, appetite, chest or abdominal distention). Although our PAC
patient cohort was more diverse in terms of clinical variables, it was nonetheless
restricted to men between the ages of 47 and 75 residing near Portland, Oregon who had
not received chemotherapy at time of urine collection (Appendix A). Second, we were
unable to obtain the specific wildtype N2 C. elegans line used by Hirotsu et al. (2015); it
is therefore possible that minor but important genetic differences existed between our
wildtype N2 C. elegans and that of Hirotsu et al. (2015) that explain the inconsistency in
our results. Third, Hirotsu et al. (2015) studied exclusively Japanese individuals, while
our cohort is likely to have consisted primarily of white Americans. If differences
between typical eastern and western diet can lead to differences in the VOC profiles of
patient urine, this could also explain C. elegans’ reduced and less consistent attraction to
cancer patient urine in our study.
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Wildtype N2 C. elegans are attracted to liver (HCC) and prostate (PAC) cancer patient
urine
The research reported by this thesis extended the work of Hirotsu et al. (2015), showing
that wildtype N2 C. elegans could, with reasonable accuracy, distinguish urine derived
from liver (HCC) and prostate (PAC) cancer patients from that derived from healthy
individuals and those with benign disease (Figs. 10-13). For both types of cancer, a
dilution of 10-2 was found to have the strongest attractive behavioral response from the C.
elegans compared to the other dilutions tested (Fig. 9). At this dilution, C. elegans were
also able to best distinguish cancer patient urine from that of the other patient types, to
which they were repulsed on average (Figs. 10-13). For the PAC cohort, we found that C.
elegans were attracted to “tumor type” scores of 2 and 3, which represented cancerous
tissue with Gleason scores of 3+3 and above, but were repulsed on average by samples
from individuals scored as 0 and 1, corresponding to normal and benign tissue (Fig. 14).
We reason that the attractive behavioral response, resulting in higher average CI values,
is a result of a differing VOC profiles between normal, benign and cancerous tissue types.
Despite the moderate success of our NSDT for distinguishing cancer from other sample
types, we found large variability in CIs both within and among urine samples regardless
of patient type. Variation in CI within individuals (i.e., among technical replicates) might
be attributed to factors including the innate variability of animal behavior, pipetting error,
and micro-environmental variations. Variation in CI among individuals could result from
the same factors in addition to those including patient diet, lifestyle, whether or not they
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had benign tumors, and the initial concentration of the collected urine sample. However,
Hirotsu et al. (2015) found no relationship between nematode chemotactic responses and
creatine concentration, a proxy for initial urine concentration. We also noticed that the
attractive behavior of the C. elegans to cancer patient urine appeared to depend upon the
number of times a urine samples was freeze-thawed prior to use in the chemotaxis assays,
with the attractive response to cancer patient urine declining with increasing freeze-thaw
cycles (data not shown). This might be as a result of VOCs being lost from the urine
samples during such cycles.
We determined the NSDT test had a sensitivity of 81% and a sensitivity of 61% for the
PAC cohort. While these values are much lower than those yielded by the NSDT of
Hirotsu et al. (2015)—sensitivity of 95.8% and specificity of 95.0%—our NSDT appears
to be comparable to the PSA test, which yielded a sensitivity and specificity of 88% and
59%, respectively, for our PAC cohort. Unlike the PSA test, however, the NSDT test can
be used other types of cancer. Although the sensitivity of NSDT was lower for HCC
compared to PAC cohorts, the limited sample size for the former and lack of clinical
diagnostics information on these patients leaves us unable to expand on the reasons
behind this outcome.
Although we found no differences among patient types in the PAC cohort in tobacco use,
BMI, or age, healthy individuals in this cohort tended to have enlarged prostates, 55.1
cm3 on average, compared to the widely accepted average size for normal prostates, 45
cm3 (Appendix A) (Mitterberger et al., 2010). Specifically, 17 of the 20 PAC patients for
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which we received prostate volume information had prostates smaller than 45 cm 3
(Appendix A). Conversely, PAC and negative screen patients had smaller than average
prostate sizes of 40.0 cm3 and 40.7 cm3, respectively. The underlying cause of the above
relationship is unknown, but may be spurious (a result of sampling from a small
population) or related to the fact that patients in the “healthy” group were those who
presented with elevated PSA, levels of which are known to be positively correlated with
prostate size (e.g., Coric et al., 2015). Likewise, we found a positive correlation between
prostate size and PSA value for both patients categorized as healthy and negative screen
(Appendix F & G). The same relationship did not exist for PAC patients, who also had
elevated PSA compared to negative screen patients (Appendices A & E). However, we
found a significant negative correlation between average CI and prostate size among the
entire data set of patients, meaning that C. elegans was increasingly attracted to urine
derived from patients with smaller prostate sizes (Appendix D). Curiously, prostate size
appears to be negatively related to PAC incidence (Al-khalil et al, 2016) with PAC more
often invading smaller prostatic glands compared to larger ones (Chen et al., 1999).
Though the PSA test remains a valuable indicator of prostate cancer, these complex
relationships alongside the fact that benign prostate tumors (Punglia et al., 2006) and
many other factors can result in elevated PSA highlight its shortcomings for the reliable
prediction of PAC.
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Nematode strain- and species-specific chemotactic responses
We further extended the work of Hirotsu et al. (2015) to test whether the efficacy of the
NSDT would demonstrate Caenorhabditis species- or strain-specificity using a subset of
the PAC cohort of urine samples. The “ancestral” N2 C. elegans strain performed in a
manner that was qualitatively similar to the standard wildtype N2 laboratory strain that
has experienced many generations of laboratory adaptation, but the lab-adapted wildtype
strain was better at distinguishing PAC from healthy and negative screen urine (Figs. 12,
13, 15 & 17 ). The causal nature of this difference is unknown but is consistent with the
presence of within-species genetic variation for chemotactic response to cancer-specific
VOCs. Notably, smaller pilot chemotaxis assays were performed with two C. elegans
natural isolates, JU2524 and MY16, neither of which exhibited any response during
NSDTs. In particular, these nematodes showed very little to no movement on average
from the point of origin on chemotaxis plates (data not shown). Chemotaxis responses
were also species-specific in that C. briggsae demonstrated no ability to differentiate
between PAC, healthy and negative screen samples, and indeed, demonstrated a weak
attraction to all three over the water control (Figs. 16 & 18). C. briggsae is quite distantly
related to C. elegans; the two species are as genetically dissimilar as human and mouse
(Stein et al., 2003; Waterston et al., 2002). These findings imply the presence of both
within- and among-species genetic variation for cancer-specific chemotactic response,
suggesting fruitful avenues for future work to identify relevant genetic loci using existing
recombinant inbred or nearly isogenic lines (RILs and NILs, respectively).
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Identifying candidate VOC ligands
It is now well understood that the human body excretes numerous VOCs in breath, blood,
skin and urine as a result of an individual’s specific metabolism (Shirasu & Touhara,
2011). The profile of such VOCs can be altered when an individual has an infection or a
metabolic, genetic or other disease (Shirasu & Touhara, 2011). By reviewing the recent
cancer metabolomics literature, I was able to identify VOCs that both differentiate cancer
patients from healthy individuals and that may also overlap those with biological
relevance for C. elegans based on their natural history and bacterivorous nature
(Appendix B). Specifically, three functional groups: alkanes, aldehydes, and ketones
were the most relevant compound types in that they were identified by multiple studies
(Appendix C). Within these functional groups, there were ten relevant primary
compounds that arose in multiple studies including: benzaldehyde, butanone, decane,
decanal, heptanone, hexanone, nonanal, nonanone, octanone, and pentanal which had the
most significant differences in concentration between healthy and cancer patients
(Appendix C). Of these, two compound types stood out: decane, an alkane, was identified
in 7/19 studies addressing five different cancer types (breast, lung, oral prostate and
renal), and benzaldehyde, the same aldehyde utilized as a positive control in this study,
was identified by 5/19 studies on four cancer types (bladder, lung, prostate and oral)
(Appendices B & C). Additionally, benzaldehyde and various compounds containing
decane (undecane; dodecane; 3,7-dimethylundecane; and hexadecane) appeared in the
exhaled breath of patients with oral cancer (Appendix B).
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Cellular concentrations of alkanes (dodecane, tetradecane and hexadecane) and
benzaldehyde are known to be elevated in cancer cells as a result of lipid peroxidation,
which occurs with inflammation and oxidative stress and is associated with higher
concentrations of reactive oxygen species (Rodrigues et al., 2018; Phillips et al., 2000;
Silva et al., 2011; Poli et al., 2010). Therefore, elevated concentrations of benzaldehyde
and alkanes signify higher oxidative stress within cancer cells (Rodrigues et al., 2018).
As a group, aldehydes are often generated as intermediates during cytotoxic processes as
a result of signal transduction, gene regulation and cell proliferation (Bouza et al., 2017).
Finally, ketones have also been identified as potential VOC biomarkers of cancer.
Matsumura et al. (2010) found that ketones were more prevalent in the urine of mice with
induced lung cancer tumors than healthy control mice, suggesting that the ketogenesic
pathway might be useful for identifying lung cancer tumors. Another literature review of
52 lung cancer VOC profile studies by Saalberg and Wolff (2016) found that 2-butanone
was the most prevalent VOC with a significant difference in concentration across these
papers. Ketones typically function within cells as fuel for mitochondria. Ketone bodies
are typically produced by mitochondria within the liver cells as a result of fasting or
exercise and transported via the bloodstream to the brain and other organs for conversion
into acetyl-CoA (Henderson, 2008; Laffel, 1999; Martinez-Outschoorn et al., 2012).
Within the brain, however, ketone bodies are also generated by astrocytes for
mitochondrial metabolism of neurons in a process known as “neuron-glia metabolic
coupling” (Guzmán, 2001; Martinez-Outschoorn et al., 2012). It has been shown that
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tumors exhibit a similar metabolic process, generating ketone bodies that fuel oxidative
phosphorylation critical for anabolic tumor growth (Martinez-Outschoorn et al., 2012).
Bacteria also emit specific VOC profiles composed of metabolic byproducts released
during growth, in addition to VOCs that provide protection against predation and are
utilized for intercellular communication (Chen et al., 2017). Likely because bacteria are
the primary food source of C. elegans, this species can detect hundreds of VOCs
including ketones, aldehydes, esters, alcohols and various aromatic compounds (Liao et
al., 2010). Specifically, E. coli, one of C. elegans’ preferred food sources in the lab, emits
volatile compounds like 2-heptanone, 2-nonanone, 2-undecanone, 1-octanol, 1-dodecanol
and indole among many others (Chen et al., 2017). Generally, methyl ketones produced
through the decarboxylation of fatty acids during pyruvate fermentation through
anaerobic conditions (Audrain et al., 2015; Ryu et al., 2003). Other microbes emit shortchain alkanes, such as decane or tetradecane, while longer-chain hydrocarbons are found
in cyanobacteria since they are capable of synthesizing branched hydrocarbons (Audrain
et al., 2015; Tellez, Schrader & Kobaisy, 2001; Ladygina, Dedyukhina & Vainshtein,
2006). The formation of alkanes in microbes requires intermediate aldehydes which are
converted into various alkanes via aldehyde deforming oxygenase (Rodriquez & Atsuml,
2014). In E. coli specifically, high levels of endogenous aldehyde reductases generally
convert aldehydes to alcohols (Rodriquez & Atsuml, 2014). This could be the reason C.
elegans are highly attracted to benzaldehyde (Bargmann et al., 1993).
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It is likely that N2 C. elegans’ preference for urine prostate and liver cancer (Figs. 10-13)
is owed to VOC profiles of cancer patients mimicking those of bacterial or other food
microbial food sources. If true, too little is known about the differences in natural history
among C. elegans isolates and among nematode species to understand why such an
attractive response would not be universal. In any case, future research could determine
which of these candidate compounds is attractive to wildtype N2 C. elegans, and whether
any of them distinguish the HCC or PAC urine sample VOC profiles from those of
control samples.
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Conclusions & Future Research
This research intended to expand upon the NSDT developed by Hirotsu et al. (2015) to
include a previously untested cancer type (HCC), control for further variables (random
nematode movement, light, surrounding odors), determine whether nematode response to
cancer was strain- or species-specific, and identify candidate cancer-specific VOCs that
may serve as attractive cues for C. elegans. We were unable to validate the findings of
Hirotsu et al. (2015) using the chemotaxis assay methodology described (Fig. 7);
however, results improved upon applying a modified version of Margie et al.’s (2013)
methodology (Fig. 8). We showed that standard wildtype N2 C. elegans and, to a lesser
extent, an ancestral strain of N2 C. elegans, were attracted to urine from patients with
either HCC or PAC compared to urine from healthy patients and those diagnosed with a
benign disease (Figs. 10-13). Additionally, our modified NSDT produced a similar
sensitivity and specificity for PAC (81% and 61%, respectively) compared to PSA tests
of the same samples (88% and 59% respectively). Beyond showing promise for early
detection of multiple cancer types, our test was also the first demonstrate that C. elegans
can distinguish samples derived from cancer patients from those of individuals with
benign disease. Further research is needed to determine if cancer-specific VOC profiles
are a result of the tumor itself or from the immunological response to the cancerous
tumor. Furthermore, since the Warburg effect is known to occur both in cancerous and
non-cancerous cell types during rapid cell proliferation (Abdel-Haleem et al., 2017),
future work should also include testing samples from patients with sepsis and other
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inflammatory diseases as a control. Indeed, when individuals with benign tumors are
removed from the PAC cohort dataset, the specificity of our NSDT increases slightly to
65%, while sensitivity remains unchanged at 81%. This could signify that C. elegans are
attracted to compounds associated with general inflammation in addition to those specific
to cancer.
We found strain- and species-specificity in chemotactic responses that point to natural
genetic variation in underlying olfactory receptor genes. Future work to perform NSDTs
on existing RIL and NIL nematode libraries, or systematic RNAi knockdown of olfactory
genes, could uncover the source of this variation. Such work, combined with chemical
interrogation of urine samples, could ultimately lead to identifying VOC ligands and their
associated neurological receptor proteins. This result also suggests that artificial selection
could yield C. elegans strains with superior ability to distinguish cancer-derived from
healthy samples. Further work would be needed to determine if within- and betweenspecies variation in response is maintained across other cancer types and stages.
Despite the promise of our results, the large variability in chemotactic responses both
among technical replicates and individuals within sample type (cancer, control) suggests
that development of an animal-based assay using non-modified wildtype nematodes is
unlikely to be worthwhile. Parallel experiments conducted by OHSU collaborators aimed
at determining which C. elegans GPCRs are activated in the presence of cancer patient
urine have been unsuccessful owing to the difficulty of enriching for membrane bound
proteins, and GPCRs specifically, in C. elegans. Rather, future GC-MS analysis of
47

fractionated HCC or PAC urine could identify candidate VOCs that distinguish cancer
from healthy samples, which could then be validated using C. elegans bioassays. Future
work may also include testing C. elegans’ chemotactic responses to the biologically
relevant concentrations of candidate compounds identified by this study as another means
of identifying the key ligand(s) that animals use to distinguish cancer from healthy and
benign tissues.
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Appendix A. Table of prostate urine sample cohort patient information.
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60

61

62

63

64

65

66

67

68

69

70

Appendix B. Table of metabolomic studies on VOC profiles from both cancer and healthy
patients
Title

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

Tisch, U., Billan,
S., Ilouze, M.,
Phillips, M.,
Peled, N. &
Haick, H. (2012)
Volatile Organic
Compounds in
Exhaled Breath
as Biomarkers
for the Early
Detection and
Screening of
Lung Cancer.
CML-Lung
Cancer, 5(4),
107-17.

2012

65

31

Breath

Lung

2-Butanone

Bouza, M.,
Gonzalez-Soto,
J., Pereiro, R., de
Vicente, J.C. &
Sanz-Medel, A.
(2017) Exhaled
breath and oral
cavity VOCs as
potential
biomarkers in
oral cancer
patients. J.
Breath Res.
016015.

2017

Diacetyl
3-Butyn-2-ol
Tetramethyl-urea
Butane, 2-methyl
1,4-Pentadiene

52

52

Breath

Oral

Undecane
dodecane
benzaldehyde
decanal
3,7-dimethyl undecane
4,5-dimethyl nonane
1-octene
hexadecane

71

Title

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

Handa, H.,
Usuba, A.,
Maddula, S.,
Baumbach, J. I.,
Mineshita, M. &
Miyazawa, T.
(2014) Exhaled
Breath Analysis
for Lung Cancer
Detection Using
Ion Mobility
Spectrometry.
PLOS One,
9(12).

2014

50

39

Breath
Tissue

Lung

n-dodecane

Wang, Y., Hu,
Y., Wang, D.,
Yu, K., Wang,
L., Zou, Y.,
Zhao, C., Zhang,
X., Wang, P. &
Ying, K. (2012)
The analysis of
volatile organic
compounds
biomarkers for
lung cancer in
exhaled breath,
tissues and cell
lines. Cancer
Biomarkers, 11,
129-137.

2012

85

158

Breath
Cell
Culture
Tissue

Lung

Pentadecanone
nonadecane
eicosane

72

Title

Lima, A. R.,
Araújo, A. M.,
D., Pinto, J.,
Jerónimo, C.,
Henrique, R., de
Lourdes Bastos,
M., Carvalho, M.
& de Pinho, P. G.
(2018)
Discrimination
between the
human prostate
normal and
cancer cell
exometabolome
by GC-MS.
Scientific
Reports, 8(5539).
Thrumani, R.,
Zakaria, A.,
Hashim, Y. Z. HY., Jeffree, A. I.,
Helmy, K. M.,
Kamarudin, L.
M., Omar, M. I.,
Shakaff, A. Y.
M., Adom, A. H.
& Persaud, K.
(2018) A study
on volatile
organic
compounds
emitted by invitro lung cancer
cultured cells
using gas sensor
array and SPMEGCMS. BMC
Cancer, 18(362).

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

2018

4

1

Cell
Culture

Prostate

pentadecane-2-one
decanoic acid
cyclohexanone
4-methylheptan-2-one
2-methylpentane-1,3diol
4-methylbenzaldehyde
1-(3,5-dimethylfuran2-yl)
ethenone
methyl benzoate
nonanoic acid

2018

2

2

Cell
Culture

Lung

Dodecane
Heneicosane
Decanal
Nonanal
2-ethyldodecanol

73

Title

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

Rodrigues, D.,
Pinto, J., Araújo,
A. M., MonteiroReis, S.,
Jerónimo, C.,
Henrique, R., de
Lourdes Bastos,
M., de Pinho, P.
G. & Carvalho,
M. (2018)
Volatile
metabolomic
signature of
bladder cancer
cell lines based
on gas
chromatographymass
spectrometry.
Metabolomics,
14(62).

2018

3

1

Cell
Culture

Bladder

Benzaldehyde

Jia, Z., Zhang,
H., Ong, C. N.,
Patra, A., Lu, Y.,
Lim, C. T. &
Venkatesan, T.
(2018) Detection
of Lung Cancer:
Concomitant
Volatile Organic
Compounds and
Metabolomic
Profiling of Six
Cancer Cell
Lines of
Different
Histological
Origins. ACS
Omega, 3, 51315140.

2018

2-nonanone

7

1

Cell
Culture

Lung

2-ethyl-1-hexanol
Benzaldehyde
2,4-Decadien-1-ol

74

Title

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

Hadi, N. I.,
Jamal, Q., Iqbal,
A., Shaikh, F.,
Somroo, S. &
Musharraf, S. G.
(2017) Serum
Metabolomic
Profiles for
Breast Cancer
Diagnosis,
Grading and
Staging by Gas
ChromatographyMass
Spectrometry.
Scientific
Reports, 7(1715).

2017

152

155

Serum

Breast

Glucopyranoside

Fages, A.,
Duarte-Salles, T.,
Stepien, M.,
Ferrari, P., …,
Jenab, M. (2015)
Metabolomic
profiles of
hepatocellular
carcinoma in
European
prospective
cohort. BMC
Med., 13(242).

2015

Tetradecane
1-(1methoxycarbonylethyl)4-(2-methyl-2hydroxypropyl)
benzene

114

222

Serum

Liver

Ethanol
Propylene Gylcol
Acetate
Tyrosine
Phenylalanine
Glutamate

75

Title

Roś-Mazurczyk,
M., Wojakowksa,
A., Marczak, L.,
Polański, K.,
Pietrowska, M.,
Polanska, J.,
Dziadziuszko, R.,
Jassem, J.,
Rzyman, W. &
Widlak, P.
(2017) Panel of
serum
metabolites
discriminates
cancer patients
and healthy
participants of
lung cancer
screening-a pilot
study. Acta
Biochimica
Polonica, 64.

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

2017

31

92

Serum

Lung

Benzaldehyde
Hydroxypyruvic
Acid
Urea

76

Title

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

Itoi, T.,
Sugimoto, M.,
Umeda, J.,
Sofuni, A.,
Tsuchiya, T.,
Tsuji, S., Tanaka,
R., Tonozuka, R.,
Honjo, M.,
Moriyasu, F.,
Kasuya, K.,
Nagakawa, Y.,
Abe, Y., Takano,
K., Kawachi, S.,
Shimazu, M.,
Soga, T., Tomita,
M. & Sunamura,
M. (2017) Serum
Metabolomic
Profiles for
Human
Pancreatic
Cancer
Discrimination.
Int. J. Mol. Sci.,
18(767).

2017

39

46

Serum

Pancreatic

Glutamatic Acid

Wang, Y.,
Jacobs, E. J.,
Carter, B. D.,
Gapstur, S. M. &
Stevens, V. L.
(2019) Plasma
Metabolomic
Profiles and Risk
of Advanced and
Fatal Prostate
Cancer. Eur Urol
Oncol, 246.

2019

Histidine
Glutamine
Trimethylamine
N-oxide
Serine

246

342

Serum

Prostate

Ethylmalonate
Butyrylcarnitine
Aspartate
Sphingomyelin
ϒ-glutamylmethionine
ϒ-glutamylglutamine

77

Title

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

Huang, J.,
Weinstein, S. J.,
Moore, S. C.,
Derkach, A.,
Hua, X., Mondul,
A. M., Sampson,
J. N. & Albanes,
D. (2019) Prediagnostic Serum
Metabolomic
Profiling of
Prostate Cancer
Survival. J
Gerontol. A. Biol
Sci Med Sci,
74(6), 853-859.

2018

197

0

Serum

Prostate

N-Oleoyl taurine

Ossoliński, K.,
Niziol, J.,
Arendowski, A.,
Ossolińska, A.,
Ossoliński, T.,
Kucharz, J.,
Wiechno, P. &
Ruman, T.
(2019) Mass
spectrometrybased
metabolomic
profiling of
prostate cancer- a
pilot study. J
Cancer
Metastasis Treat,
5(1).

2019

5

15

Serum
Urine
Interstitial
Fluid

Prostate

Cholesterol Sulfate
(Urine)
Triglyceride (Urine)
Cholesterol and
triglylcerides (Serum)
Amino Acids (Serum)

78

Title

Wang, D., Wang,
C., Pi, X., Guo,
L., Wang, Y., Li,
M., Feng, Y.,
Lin, Z., Hou, W.
& Li, E. (2016)
Urinary volatile
organic
compounds as
potential
biomarkers for
renal cell
carcinoma.
Biomedical
Reports, 5, 6872.

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

2016

22

25

Urine

Renal

Phenol
decanal
1,6-dioxacyclododecane7,12-dione
1-bromo-1(3-methyl1-pentenylidene)2,2,3,3-tetramethylcyclopropane
nonanal
3-ethyl-3methylheptane
isolongifolene-5-ol
2,5-cyclohexadiene1,4-dione, 2,6-bis
(1,1-dimethylethyl)
tetradecane
aniline
2,6,10,14-tetramethyl
-pentadecane
styrene
4-heptanone
dimethyl silanediol

79

Title

Santos, P. M.,
Sánchez, M. N.,
Pozas, A. P. C.,
Pavón, J. L. P.,
Cordero, B. M.
(2017)
Determination of
ketones and ethyl
acetate—a
preliminary study
for the
discrimination of
patients with
lung cancer. Anal
Bioanal Chem,
409, 5689-5696.
Khalid, T.,
Aggio, R.,
White, P.,
Costello, B.,
Persad, R., AlKateb, H., Jones,
P., Probert, C. S.
& Ratcliffe, N.
(2015) Urinary
Volatile Organic
Compounds for
the Detection of
Prostate Cancer.
PLOS One,
10(11),
e0143283.

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

2017

12

12

Urine

Lung

ethyl acetate
3-heptanone
3-octanone

2015

59

43

Urine

Prostate

2,6-dimethyl7-octen-2-ol
pentanal
(Valeraldehyde)
3-octanone
2-octanone

80

Title

Gao, Q., Su, X.,
Annabi, M. H.,
Schreiter, B. R.,
Prince, T.,
Ackerman, A.,
Morgas, S.,
Williams, H. &
Lee, W. Y.
(2019)
Application of
Urinary Volatile
Organic
Compounds
(VOCs) for the
Diagnosis of
Prostate Cancer.
Clin Genitourin
Cancer, 17(3)
183-190.

Year
Published

Total
Cancer
Samples

Total
Control
Samples

Sample
Type(s)

Cancer
Types

VOCs

2019

53

22

Urine

Prostate

1,1,1,5,5,5hexamethyl-3,3-bis
[(trimethylsilyl)
oxy]Trisiloxane
1-Propylpentachlorotriphosphazene
4-Nitro-4’Chlorodiphenylsulfoxide
1,1,3,3,5,5,7,7,9,9decamethylpentasiloxane
2,6-di-t-butyl-4hydroxymethylene2,3,5,6-detetrahydro
cyclohexanone
Phthalic acid,
bis(7-methyloctyl) ester

81

Appendix C. Table of specific VOCs from the metabolomic studies that were
significantly different between cancer and healthy patients
Primary
compound

Additional compounds
containing primary
compound

Functional
Group

Number of
Papers
Referenced
(Out of 19
Papers)

Decane

3,7-dimethylundecane
dodecane
hexadecane
nonadecane
tetradecane
undecane
4-methylbenzaldehyde
Hexadecanal

Alkane

7

Number of
Cancer
types
appeared
(Out of 8
Cancer
types)
5

Aldehyde
Aldehyde
Aldehyde
Ketone

5
2
2
2

4
2
2
2

2,6-di-t-butyl-4hydroxymethylene-2,3,5,6detetrahydrocyclohexanone
Cyclohexanone
3-heptanone
4-heptanone

Ketone

2

1

Ketone

2

2

2-butanone
2-nonanone

Ketone
Ketone
Aldehyde

1
1
1

1
1
1

Benzaldehyde
Decanal
Nonanal
Octanone
Hexanone

Heptanone
Butanone
Nonanone
Pentanal

2-octanone
3-octanone

82

Appendix D. Multivariate correlation of entire data set with three sample types
(Healthy, Negative Screen and PAC

Average CI
PSA

Average
CI
1.000

PSA
0.0329
0.6314
1.000

Prostate
Size
-0.3066
0.0273

Tobacc
o Use
-0.0465
0.7193

Tumor
Type
0.2505
0.0409

BMI

Age

-0.0408
0.7428

0.0101
0.9352

0.2747
0.0403
1.000

-0.0635
0.4516
0.0391
0.9977

0.6016
<0.0001
-0.0654
0.5295

-0.0805
0.5473
-0.0167
0.9470

-0.0207
0.6676
-0.0478
0.5214

Prostate
Size

0.0329
0.6314
-0.3066
0.0273

0.2747
0.0403

Tobacco
Use

-0.0465
0.7193

-0.0635
0.4516

0.0391
0.9977

1.000

0.0835
0.5012

-0.1911
0.1226

-0.0682
0.5764

Tumor
Type

0.2505
0.0409

0.6016
<0.0001

-0.0654
0.5295

0.0835
0.5012

1.000

-0.0325
0.7937

-0.0323
0.7955

BMI

-0.0408
0.7428

-0.0805
0.5473

-0.0167
0.9470

-0.1911
0.1226

-0.0325
0.7937

1.000

-0.1076
0.3862

Age

0.0101
0.9352

-0.0207
0.6676

-0.0478
0.5214

-0.0682
0.5764

-0.0323
0.7955

-0.1076
0.3862

1.000
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Appendix E. Multivariate correlation of PAC patient data

Average CI

Average
CI
1.0000

PSA
0.0128
0.9562

Prostate
Size
-0.3034
0.1929

Tobacco
Use
0.1087
0.6391

Tumor
Type
-0.081
0.7271

BMI

Age

-0.2688
0.2387

0.1510
0.5136

PSA

0.0128
0.9562

1.0000

-0.0781
0.9314

-0.1059
0.6479

0.2948
0.1946

-0.2050
0.3728

0.1476
0.5231

Prostate
Size

-0.3034
0.1929

-0.0781
0.9314

1.0000

0.2294
0.5325

-0.5021
0.0629

0.1518
0.9308

0.0205
0.9944

Tobacco
Use

0.1087
0.6391

-0.1059
0.6479

0.2294
0.5325

1.0000

0.1132
0.6251

-0.1859
0.4197

-0.1694
0.4629

Tumor
Type

-0.081
0.7271

0.2948
0.1946

-0.5021
0.0629

0.1132
0.6251

1.0000

-0.2803
0.2184

-0.1684
0.4657

BMI

-0.2688
0.2387

-0.2050
0.3728

0.1518
0.9308

-0.1859
0.4197

-0.2803
0.2184

1.0000

-0.1519
0.5110

Age

0.1510
0.5136

0.1476
0.5231

0.0205
0.9944

-0.1694
0.4629

-0.1684
0.4657

-0.1519
0.5110

1.0000
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Appendix F. Multivariate correlation of healthy patient data
Average
CI

PSA

Prostate
Size

Tobacco
Use

Tumor
Type

BMI

Age

Average CI

1.0000

-0.2947

-0.2081
0.2434

0.0774
0.7528

0.0000

0.1214
0.6204

0.1241
0.6127

PSA

-0.2947
0.2207

1.0000

0.5447
0.0227

0.0242
0.9217

0.0000

-0.2143
0.3782

0.1736
0.5057

Prostate Size

-0.2081
0.2434

0.5447
0.0227

1.0000

-0.1931
0.5904

0.0000

0.0242
0.8257

-0.0543
0.6903

Tobacco Use

0.0774
0.7528

0.0242
0.9217

-0.1931
0.5904

1.0000

0.0000

-0.0656
0.7898

-0.1248
0.6106

Tumor Type

0.0000

0.0000

0.0000

0.0000

1.0000

0.0000

0.0000

BMI

0.1214
0.6204

-0.2143
0.3782

0.0242
0.8257

-0.0656
0.7898

0.0000

1.0000

-0.1627
0.5057

Age

0.1241
0.6127

0.1736
0.5057

-0.0543
0.6903

-0.1248
0.6106

0.0000

-0.1627
0.5057

1.0000
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Appendix G. Multivariate correlation of negative screen patient data
Average
CI

PSA

Prostate Tobacco Use
Size

Tumor
Type

BMI

Age

Average CI

1.0000

-0.0474 -0.4481
0.6040 0.4657

-0.3087
0.1590

-0.0853
0.6721

0.0074
0.9710

-0.2295
0.2494

PSA

-0.0474
0.6040

1.0000

0.5035
0.0473

-0.1975
0.4760

0.5390
0.0618

0.1719
0.7726

-0.2869
0.2436

Prostate Size

-0.4481
0.4657

0.5035
0.0473

1.0000

0.2673
0.5483

0.3294
0.3276

-0.2113
0.9330

0.2511
0.9235

Tobacco Use

-0.3087
0.1590

-0.1975
0.4760

0.2673
0.5483

1.0000

0.2822
0.3046

-0.2865
0.1674

0.0148
0.9734

Tumor Type

-0.0853
0.6721

0.5390
0.0618

0.3294
0.3276

0.2822
0.3046

1.0000

0.1620
0.4194

-0.0554
0.7839

BMI

0.0074
0.9710

0.1719
0.7726

-0.2113
0.9330

-0.2865
0.1674

0.1620
0.4194

1.0000

-0.0242
0.9045

Age

-0.2295
0.2494

-0.2869
0.2436

0.2511
0.9235

0.0148
0.9734

-0.0554
0.7839

-0.0242
0.9045

1.0000
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